No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Soligenix Shares Are Trading Lower After the Company Announced Its Interim Results From the Ongoing Open-label Investigator-initiated Study of HyBryte.
Soligenix Announces Positive Data For Extended HyBryte In Early-stage Cutaneous T-cell Lymphoma
Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
Positive Outcome in 75% of CTCL Patients Treated With HyBryte for 18 Weeks
12 Health Care Stocks Moving In Friday's After-Market Session
Soligenix Reports Publication Describing Preclinical Efficacy Of CiVax - Quick Facts